<p>2025 年 9 月 30 日，ESSA Pharma Inc.（纳斯达克代码：EPIX）公布了关于其与 XenoTherapeutics Inc.的商业合并协议的重要更新。两者之间的合作预计将带来变革性的变化，南旧金山和温哥华将成为这些发展的重要中心。这一举措标志着 ESSA 向前迈出了关键一步，展示了其在生物科技领域对合作与创新的承诺。这一战略合并将产生广泛的影响，体现了行业向有影响力、以使命为驱动的事业不断演变的趋势。</p>

ESSA银行

<p>ESSA Pharma Inc.（纳斯达克代码：EPIX）已就其与 XenoTherapeutics Inc.的业务合并协议提供了最新进展。此次合作旨在推动生物技术领域的变革，以南旧金山和温哥华为关键中心。这一战略性合并突显了 ESSA 对创新和合作的承诺，标志着行业向有影响力的、以使命为驱动的倡议的重要演变</p>

<p>On September 30, 2025, ESSA Pharma Inc. (NASDAQ: EPIX) revealed a significant update regarding its Business Combination Agreement with XenoTherapeutics Inc. The collaboration between the two entities is expected to bring about transformative changes, with South San Francisco and Vancouver serving as significant hubs for these developments. This initiative marks a crucial step forward for ESSA, showcasing its commitment to partnerships and innovation in the biotech sector. The strategic merger is set to have wide-reaching implications, exemplifying the ongoing evolution of the industry towards impactful, mission-driven endeavors.</p>
<div class="lb-trans"><p>2025 年 9 月 30 日，ESSA Pharma Inc.（纳斯达克代码：EPIX）公布了关于其与 XenoTherapeutics Inc.的商业合并协议的重要更新。两者之间的合作预计将带来变革性的变化，南旧金山和温哥华将成为这些发展的重要中心。这一举措标志着 ESSA 向前迈出了关键一步，展示了其在生物科技领域对合作与创新的承诺。这一战略合并将产生广泛的影响，体现了行业向有影响力、以使命为驱动的事业不断演变的趋势。</p>
</div>

ESSA Pharma provides update on Supreme Court application for amended interim order regarding its Business Combination Agreement with XenoTherapeutics Inc. (NASDAQ: EPIX)

ESSA Pharma 就其与 XenoTherapeutics Inc. (NASDAQ: EPIX) 的业务合并协议修订临时命令的最高法院申请提供了最新信息